Electrophysiologic effects of the calcium antagonist isradipine, a double-blind placebo-controlled study.
The electrophysiologic effects of the calcium channel antagonist isradipine in comparison to placebo were evaluated in a double-blind study with 9 patients in each group. The two patient groups were not different with respect to their cardiac disease, baseline electrophysiologic parameters, or blood pressure. Isradipine significantly decreased the systolic (P less than 0.01) and diastolic (P less than 0.05) blood pressure, whereas sinus cycle length was significantly (P less than 0.05) decreased in the placebo group and the isradipine group with no difference between the groups. The influence of isradipine and placebo on sinus node recovery time, effective refractory period of the atrioventricular node, intranodal conduction time (AH interval) and PR interval were not significant. In conclusion, isradipine significantly decreased systolic and diastolic blood pressure. The decrease in sinus cycle length after intravenous isradipine was not significantly different from the decrease seen in the placebo group. Atrioventricular conduction was not significantly affected.
Kühlkamp
V
V
Medizinische Klinik Abteilung III, Eberhard-Karls-Universität Tübingen, F.R.G.
Maier
F
F
Seipel
L
L
D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002304:Cardiac Pacing, Artificial; D003864:Depression, Chemical; D004311:Double-Blind Method; D004341:Drug Evaluation; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D011725:Pyridines; D017275:Isradipine